ChromaDex (NASDAQ:CDXC) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of ChromaDex (NASDAQ:CDXC) in a research report released on Monday morning,Benzinga reports. They currently have a $11.00 target price on the stock.

CDXC has been the topic of a number of other research reports. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th. LADENBURG THALM/SH SH upped their target price on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a report on Wednesday, March 5th.

ChromaDex Price Performance

Shares of CDXC opened at $7.94 on Monday. The company has a market capitalization of $617.34 million, a price-to-earnings ratio of 794.79 and a beta of 2.21. ChromaDex has a fifty-two week low of $2.31 and a fifty-two week high of $9.18. The business’s 50-day moving average is $6.06 and its 200-day moving average is $5.39.

Institutional Investors Weigh In On ChromaDex

Large investors have recently made changes to their positions in the company. Barclays PLC grew its stake in shares of ChromaDex by 322.1% in the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after buying an additional 53,472 shares in the last quarter. Sargent Investment Group LLC bought a new stake in shares of ChromaDex in the 4th quarter valued at approximately $263,000. FMR LLC bought a new stake in shares of ChromaDex in the 3rd quarter valued at approximately $55,000. JPMorgan Chase & Co. grew its stake in shares of ChromaDex by 11.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock valued at $1,211,000 after buying an additional 33,150 shares in the last quarter. Finally, State Street Corp grew its stake in shares of ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.